PATENT CLAIM ANALYSIS

Application Number: 15902886
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "013700"]

Abstract:
The present disclosure provides unit dose formulations and methods to reduce, stop or prevent bleeding in a patient undergoing anticoagulant therapy with a factor Xa inhibitor. The methods entail at least partial neutralization of the factor Xa inhibitors The unit dose formulations and methods of the present disclosure can be effective even after actual bleeding has initiated.

Claim (Index 28):
A method of reducing or ceasing bleeding in a subject undergoing an anticoagulant therapy with an indirect factor Xa inhibitor, comprising administering to the subject a therapeutically effective amount of a formulation comprising a two-chain polypeptide comprising the amino acid sequence of SEQ ID NO. 3 or a polypeptide having at least 80% sequence identity to SEQ ID NO. 3, such that the polypeptide reduces from about 20% to about 95% of the level of an anti-fXa pharmacodynamic marker of the indirect factor Xa inhibitor, wherein the polypeptide that has at least 80% sequence identity to SEQ ID NO. 3 (a) has reduced procoagulant activity compared to wild-type factor Xa and (b) does not assemble into a prothrombinase complex.

Metadata:
- Claim Count in Document: 84.0
- Percentile: 88.0
- Lexical Diversity: 1.39535
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12836536', '13414499', '13889014', '12239651', '15435086']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8588270722405653
- 35 USC 102 Novelty (BERT): 0.6010294136765657
- Combined Prediction Score: 0.8330473063841654
- Mean Citation Score: 601.027832
- Max Citation Score: 613.67346
- Similarity Product: 453.8010905142045

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test